Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs
申请人:Boehringer Ingelheim Pharma KG
公开号:US20040058978A1
公开(公告)日:2004-03-25
The present invention relates to new substituted indolinones of general formula
1
wherein
X and R
1
to R
5
are defined as in claim 1, the isomers and the salts thereof which have valuable properties.
The above compounds of general formula I wherein R
1
denotes a hydrogen atom, a C
1-3
-alkyl group or a prodrug group have valuable pharmacological properties, particularly an inhibiting effect on various kinases, on viral cyclin and on receptor tyrosine kinases, and the other compounds of the above general formula I wherein R
1
does not represent a hydrogen atom, a C
1-3
-alkyl group or a prodrug group are valuable intermediate products for the preparation of the abovementioned compounds.
本发明涉及一种新的通式1的取代吲哚酮,其中X和R1至R5的定义如权利要求书1中所述,其异构体和盐具有有价值的性质。通式I中的上述化合物,其中R1表示氢原子,C1-3-烷基或前药基,具有有价值的药理学性质,特别是对多种激酶、病毒细胞周期蛋白和受体酪氨酸激酶具有抑制作用,上述通式I中R1不表示氢原子、C1-3-烷基或前药基的其他化合物是制备上述化合物的有价值中间体。